Skip to Content

ST-246 Approval Status

FDA Approved: No
Brand name: ST-246
Company: SIGA Technologies, Inc.
Treatment for: Exposure to Smallpox Virus

ST-246 is an orally active, smallpox antiviral in development to treat individuals exposed to the smallpox virus in the event of an outbreak.

Development Status and FDA Approval Process for ST-246

Apr  4, 2008SIGA Initiates Manufacture of ST-246 NDA Registration Batches
Mar 24, 2008SIGA Files Application Supporting Emergency Use Approval for ST-246

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.